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Mycobacterium avium subsp. paratuberculosis (MAP) is a zoonotic pathogen, a very slow growing bacterium which
is difficult to isolate and passage in conventional laboratory culture. Although its association with Johne’s disease or
paratuberculosis of cattle is well established, it has been only putatively linked to Crohn’s disease in humans.
Further, MAP has been recently suggested to be a trigger for other autoimmune diseases such as type-1 diabetes
mellitus (T1DM). Recently, some studies have indicated that exposure to MAP is associated with elevated levels of
antibodies against MAP lysate although the exact mechanism and significance of the same remains unclear.
Further, the cytokine profiles relevant in MAP associated diseases of humans and their exact role in the
pathophysiology are not clearly known. We performed in vitro cytokine analyses after exposing different cultured
human cells to the whole cell lysate of MAP and found that MAP lysate induces secretion of cytokines IL-1β, IL-6,
IL-8, IL-10 and TNF-α by human peripheral blood mononuclear cells (PBMCs). Also, it induces secretion of IL-8 by
cultured human stomach adenocarcinoma cells (AGS) and PANC-1(human pancreatic carcinoma cell line) cells. We
also found that MAP lysate induced cytotoxicity in PANC-1cells. Collectively, these results provide a much needed
base-line data set of cytokines broadly signifying a MAP induced cellular response by human cells.Introduction
Mycobacterium avium subsp. paratuberculosis (MAP)
causes chronic inflammation of intestines in cattle and
other ruminants, known as Johne’s disease (JD) [1]. MAP
infection in JD leads to an early proinflammatory and
cytotoxic response (Th-1 like) that further escalates to a
predominant antibody based immune response (Th-2
like). Furthermore, studies have demonstrated that MAP
infected cattle show enhanced IL-8 gene expression in
intestinal tissues when compared to controls [2]. Studies
on ovine macrophages indicated that MAP can induce
low level apoptosis but not cytotoxicity (necrosis) [3].
MAP, an obligate zoonotic pathogen is also linked to a
similar type of enteritis as JD, in humans, known as
Crohn’s disease [4,5], wherein, the symptoms include
abdominal pain, ulcers and diarrhoea (with bloody epi-
sodes) [6]. Moreover, this disease is also considered as* Correspondence: sandhyarani317@gmail.com; ahmed.nizi@gmail.com
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reproduction in any medium, provided the oran autoimmune disorder with inflammation contributed
by Th1 cytokine responses [7]. Studies have also suggested
that Crohn’s disease might have a genetic link such as
mutation in the NOD2 gene [8]. The epidemiological
studies have indicated that Crohn’s disease is more com-
mon in the temperate regions of the globe with intensive
farming [9]. Diseased animals with clinical JD may shed
MAP in their milk and faeces, and it is observed that
MAP resists chlorination and pasteurization [10]. The
existence of MAP in sphaeroplast form in addition to its
bacillary form ensures survival [11]. ELISA studies have
indicated correlation between MAP infection and type 1
diabetes mellitus (T1DM) [12,13]. It has been reported
that children exposed to MAP in early life have low inci-
dence of certain autoimmune diseases and exposure to
MAP is associated with raised antibody levels against
MAP [14-16].
In both cattle and humans, there is a long delay between
the MAP infection and occurrence of the clinical disease.
The clinical manifestation could ultimately be the out-
come of various cytokine responses of an activated. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[17]. Both Crohn’s disease and Type 1 diabetes are char-
acterized by inflammatory responses, and, genetic predis-
position alone cannot explain their acquisition. Several
factors such as gut microflora, pathogens, dietary ele-
ments and environmental toxins are being considered in
the development of these diseases although MAP has
emerged as an important microbial trigger.
Given some association studies that putatively link
MAP to T1DM or Crohn’s, not many efforts have been
directed at identifying the cytokine profiles pathogno-
monic of MAP infection in humans. In this preliminary
study we were interested to analyze cytokine coordinates
relevant to chronic autoimmune disease pathology by
in vitro studies of different human cells after treatment
with whole cell lysate of MAP.Results and discussion
Responses of the PBMCs
We performed a set of experiments including cytokine
analysis with MAP lysates. These included the treatment
of human PBMCs with MAP lysate that resulted in an
increased secretion of cytokines IL-1β, IL-6, IL-8, IL-10
and TNF-α in a dose and time dependent manner
(Figure 1A). The cytokine responses from the human
PBMCs were from two normal humans who presumably
have not been exposed to MAP. Hence the cytokine
responses were the innate ones. We do believe that these
PBMCs may not be naïve to the mycobacterial antigens
either because BCG vaccination is a normal practice in
India or due to a saprophytic mycobacterial exposure.
This could be one of the possible reasons as to why the
PBMCs revealed highly significant cytokine responses.Responses of the cell lines
Treatment of AGS cells and PANC-1 cells with MAP
lysate resulted in increased secretion of IL-8 in a dose
and time dependent manner (Figure 1B and Figure 1C),
but, secretion of other cytokines was not observed (data
not shown). IL-8 is a chemotactic factor that mediates
recruitment and activation of the cells of inflammation
in the lesions of various types of inflammatory processes
[18]. TNF-α and IL-1β are involved in Th-1 response;
IL-10 is involved with Th-2 response. Although, IL-6
mediates acute phase response but when its function
persists as proinflammatory cytokine, then acute inflam-
mation turns into a chronic one. Further, in autoimmune
disorders, IL-6 is not only involved in the maintenance
of inflammation but also in modification of the immune
responses [19]. These points suggest that MAP lysate
activates both Th-1 and Th-2 responses. TNF-α secreted
by macrophages induces inflammation; increased levels
of TNF-α have been found to be associated with thedevelopment of Crohn’s disease [20]. Further, signifi-
cantly higher concentrations of TNF-α were found in
MAP-positive Crohn’s disease patients [21]. Plasma con-
centration of IL-6 was significantly high in patients with
Crohn’s disease when compared to healthy controls [22].
Previous studies have shown that monocytes isolated
directly from the blood of T1DM individuals secreted
proinflammatory cytokines such as IL-1β and IL-6
thereby triggering the expansion of Th17 cells that are
intimately involved in the development of autoimmune
diseases [23]. Nevertheless, in patients with recent onset
of T1DM and also in animal models of T1DM, increased
expression of TNF-α and IL-1β was observed in pan-
creas [24]. We do not believe that the observed cytokine
responses could be due to other confounding triggers
(such as Mycobactin J used in bacterial culture media or
the foetal bovine serum used in cell culture), as we have
taken enough care to ensure fool proof protocols and
ensured essential centrifugation and washing steps to
move away any residual media or living bacterial cells.Cytotoxic effects of the MAP lysate
To determine the possible cytotoxic effects of MAP
lysate, we performed MTT assay with human PBMCs,
AGS cells and PANC-1 cells after treatment with MAP
lysate. The results indicated that MAP lysate caused no
cytotoxic effects to the human PBMCs and AGS cells
(Figure 2A and Figure 2B). However, when PANC-1 cells
were treated with MAP lysate, no cytotoxic effect was
observed up to 48 hr, but, a dose dependent cytotoxic
effect was observed at 72 and 96 hr (Figure 2C). This
was further confirmed by DAPI staining of PANC-1
cells on treatment with MAP lysate; this observation
indicates cell membrane rupture representing necrosis
(Figure 3). In view of these findings, we believe that
MAP lysates exert differential effect on different types
of epithelial cells i.e. AGS and PANC-1 cells. Further,
cell viability was not affected in all the cell types when
MTT assay was performed after treatment with other
mycobacterial cell lysates such as the crude antigen pre-
paration of Mycobacterium smegmatis (data not shown).Conclusions and prospective
Taken together, these observations portray cytokine coor-
dinates of the treatment of cultured human cells with
MAP lysate which were documented for diverse cell types
using cytometry and imaging experiments. MAP lysate
induced dose and time dependent cytotoxicity in PANC-1
cells. Further, we found whole cell lysate preparation to
be an important ‘global’ antigen to perform cytokine
assays probably indicative of the cellular responses of
mammalian cells rather than employing individual MAP
proteins to interact with cultured cells. The latter is both
Figure 1 (A) Cytokine analysis of culture supernatants of human peripheral blood mononuclear cells (PBMCs) upon treatment with
MAP lysate indicated increased secretion of IL-1β, IL-6, IL-8, IL-10 and TNF-α (B) Cytokine analysis of culture supernatants of AGS cells
resulted in increased secretion of IL-8 (C) Cytokine analysis of the culture supernatants of PANC-1 cells resulted in increased secretion
of IL-8 in a dose and time dependent manner. The statistical analysis (of untreated fractions and those with the treatment of different
concentrations of MAP lysate and LPS) corresponding to PBMCs at 24 and 48 hr and AGS and PANC-1 at 24 hr, 48 hr and 72 hr resulted in
p< 0.05 indicating significant increase in the secretion of cytokines.
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said, some issues remain. It is difficult to ascertain if the
responses of MAP lysate-treated cells represent what
occurs in vivo in MAP-associated diseases. Are these
observations unique to MAP lysates? What are thebioactive components responsible for the observed re-
sponse? Is the same response induced when the gut is
challenged with MAP or the crude MAP preparations
used for immunization? Although we do not have full
answers to these obvious questions, it will be possible to
Figure 2 (A) MTT assay of PBMCs indicating no cytotoxic effect upon treatment with MAP lysate (B) MTT assay of AGS cells after
treatment with MAP lysate resulted in no cytotoxicity (C) MTT assay of PANC-1 cells on treatment with MAP lysate indicated no
cytotoxicity at 48 hr but significant cytotoxicity was observed in PANC-1 cells at 72 hr and 96 hr. The statistical analysis between
untreated and with different concentration of MAP lysate of PBMCs and AGS cells at 48 hr, 72 hr and 96 hr resulted in p > 0.05 indicating there is
no statistically significant cytotoxicity upon treatment with MAP lysate when compared to untreated. The statistical analysis between untreated
fractions of PANC-1 and those treated with different concentrations of MAP lysate at 48 hr resulted in p > 0.05 indicating that there is no
significant cytotoxicity on treatment with MAP lysate but the statistical analysis of PANC-1 untreated and treated with different concentration of
MAP lysate at 72 hr and 96 hr indicated p < 0.05 indicating significant cytotoxicity. The OD570 values are represented as % cell viability and one of
the OD570 of the untreated cells is taken as 100% viability for each cell types in MTT assay.
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robust in vitro model of MAP infection in the near future.
Materials and methods
Ethics statement
This study did not entail any specific ethical approvals
although informed consents were obtained from the 2
healthy donors of the human peripheral blood mono-
nuclear cells (PBMCs).
Preparation of MAP lysate
The MAP strain 1515(ATCC43015) was cultured in 7 H9
medium (Sigma-Aldrich) supplemented with 10% ADC
(albumin dextrose catalase), 0.05% Tween80 (Sigma-
Aldrich). and Mycobactin J (2 μg/ml) and incubated at37°C until an approximate OD of 500 was achieved. The
culture was then centrifuged at 4000 g for 20 min and
the cell pellet washed twice with 1XPBS. The cells were
subjected to disruption on ice by using ultrasonic
homogenizer. The resultant lysate was then centrifuged
at 10000 × g for 20 min to remove unbroken cells and
cell debris. The supernatant was decanted and trans-
ferred into a fresh tube. The protein concentration was
determined by Bradford’s reagent.
Cytokine analysis of human PBMCs, AGS and PANC-1 cells
The heparinised blood was collected from two healthy
individuals and PBMCs were isolated from the method
previously described [25]. A total of about 0.5 million
cells per ml of RPMI1640 media (Hyclone) containing
Figure 3 DAPI stained PANC-1 cells on treatment with MAP lysate indicated cell membrane rupture representing necrosis when
compared to untreated PANC-1 cells.
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with different concentrations of MAP lysate (1 μg, 5 μg,
10 μg) as compared to treatment by 1 μg of E. coli LPS
(Sigma) used as a positive control. The culture superna-
tants were collected at 24 and 48 hr respectively and
were stored at −80°C until the cytokine analysis was per-
formed. A total of 0.5 million AGS cells (NCCS, Pune,
India) per ml of HAMS F-12 media (Hyclone) contain-
ing 10% FBS and 0.5 million of PANC-1 cells (ATCC)
per ml of DMEM high glucose (Hyclone) media contain-
ing 10% FBS were treated with different concentrations
of MAP lysate (1 μg, 5 μg, 10 μg) and with 1 μg of LPS
(positive control). The culture supernatants were col-
lected at 24, 48 and 72 hr in each case and stored at
−80°C until the cytokine analysis was performed. The
cytokines IL-1β, IL-6, IL-8, IL-10, and TNF-α in the cul-
ture supernatants were analysed by BD CBA flex kit (BD
Biosciences, USA). The acquisition of the sample was
carried out in a BD FACS Canto II flow cytometer by
using BD FACS diva software and the analysis was
carried out by plotting the standard curve for each
cytokine by using FCAP array software (Soft Flow/BD
Biosciences).
MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide) assay of PBMCs, AGS and PANC-1
cells upon treatment with MAP lysate
A total of about 0.05 million cells of human PBMCs per
200 μl of RPMI1640 media (Hyclone) containing 10%FBS (Hyclone), 0.05 million AGS cells per 200 μl of
HAMS F-12 media (Hyclone) containing 10% FBS
(Hyclone) and 0.05 million PANC-1 cells per 200 μl of
DMEM High glucose (Hyclone) containing 10% FBS
(Hyclone) were treated with different concentrations
(1 μg, 5 μg, 10 μg) of MAP lysate. MTT assay was car-
ried out after 48, 72 and 96 hr respectively. To the cells
containing media, 50 μl of 5 mg/ml of MTT (Sigma)
was added and incubated at 37°C for 4 hr.Then the plate
was centrifuged at 2000 rpm for 10 min.The supernatant
was discarded and 200 μl of 40 mM acidified isopropa-
nol was added and incubated at 37°C for 15 min. The
purple color thus formed was measured at 570 nm in
ELISA reader (infinite M200 TECAN).
DAPI (4′, 6-diamidino-2-phenylindole) staining
of PANC-1 cells
A total of about 0.05 million of PANC-1 cells were
grown on the cover slip and treated with 10 μg MAP
lysate for 72 hr. The media from untreated cells and
treated cells was removed and the cells washed with 1X
PBS. The cells were then fixed by treatment with 4%
paraformaldehyde and incubated for 15 min at 37°C.
The cells were then washed thrice with 1X PBS. The
cells were subsequently treated for 15 min at 37°C with
0.2% Triton-X 100 in PBS to induce permeability. The
cells were then washed thrice with 1X PBS. DAPI with
antifade reagent was subsequently added to the cells on
the coverslip. The coverslip was then carefully reverted
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under a fluorescence microscope (Leica).
Statistical analysis
The student’s t–test was performed using Graph pad
Prism 5.0 software. The p-value was calculated for each
experiment which was conducted in triplicates.
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